• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
GYN
CMECNE

CDC Guidelines on How to Start Combined Hormonal Contraceptives

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Discuss the initiation timing and back-up contraceptive requirements of combined hormonal contraceptives
2. Manage clinical scenarios where women are switching from other contraceptives, including IUDs to combined hormonal contraceptives

Estimated time to complete activity: 0.5 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Feb 19 2019 through 07/15/2022, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.4 contact hours.

Designated for 0.2 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Read Disclaimer & Fine Print

CLINICAL ACTIONS

Combined hormonal contraceptives contain both estrogen and a progestin. This contraceptive category includes combined oral contraceptives, transdermal patches and vaginal rings. They are effective when taken as directed, reversible and can be used by women of all ages.  It is important to alert women that they will not protect against STDs and other preventative measures will be required to protect against infections.  The following assumes there are no contraindications to estrogen component (e.g., breast cancer, hyperlipidemia, liver disease etc.). Only BP is “essential and mandatory” and when BP cannot be measured by a provider, a measurement obtained in other setting can be reported by the woman to her provider. The following are highlights from the CDC recommendations on initiation:  

Initiation – Criteria and Timing

Obesity

Patient with Amenorrhea (Not Postpartum)

Postpartum (Breastfeeding)

Postpartum (Not Breastfeeding)

Postabortion (Spontaneous or Induced)

Need for Follow-up

Switching from Another Contraceptive Method

Switching from an IUD

VTE WARNING Category 3 or 4

Initiation – Criteria and Timing  

CDC Criteria to determine with ‘reasonable certainty’ that woman is not pregnant (≥1 of the following)  

  • ≤7 days after the start of normal menses 
  • No sexual intercourse since the start of last normal menses 
  • Correctly and consistently using a reliable method of contraception 
  • ≤7 days after spontaneous or induced abortion 
  • Within 4 weeks postpartum 
  • Fully or nearly fully breastfeeding (exclusively breastfeeding or the vast majority [≥85%] of feeds are breastfeeds), amenorrheic, and <6 months postpartum  

Timing  

  • Start at any time if ‘reasonably certain’ not pregnant criteria are met  

Back-Up Contraception 

  • If combined hormonal contraception begun within the first 5 days since menstrual bleeding started 
    • No additional contraceptive protection is needed 
  • If combined hormonal contraception started >5 days since menstrual bleeding started 
    • Abstain from sexual intercourse or  
    • Use additional contraceptive protection for the next 7 days 

Obesity

  • Combined hormonal contraceptives are a category MEC 2 and therefore can be prescribe to women regardless of BMI
  • Obesity is a risk factor for VTE, but lower than risk from pregnancy

Patient with Amenorrhea (Not Postpartum) 

  • Timing 
    • Start at any time if ‘reasonably certain’ not pregnant criteria  
  • Back-up contraception 
    • Abstain from sexual intercourse or  
    • Use additional contraceptive protection for the next 7 days 

Postpartum (Breastfeeding) 

  • Timing 
    • Start when the woman is medically eligible (MEC guidance) and meets ‘reasonably certain’ not pregnant criteria  
  • US MEC postpartum guidance (combined hormonal contraceptives)  
    • Avoid combined hormonal contraceptives during the first 3 weeks (risk of VTE)  
    • Avoid combined hormonal contraceptives during the first 4 weeks (concerns regarding breastfeeding performance)  
    • Caution: Women who are postpartum with additional risk factors for VTE should not use combined hormonal contraceptives 4–6 weeks after delivery (please see ‘Primary Sources’ and ‘Related ObG Topics below for further guidance on medical eligibility)
  • Back-up contraception  
    • <6 months postpartum, amenorrheic, and fully or nearly fully breastfeeding (exclusively breastfeeding or the vast majority [≥85%] of feeds are breastfeeds)  
      • no back-up needed 
    • If not in the above category, and patient is ≥21 days postpartum and has not experienced return of her menstrual cycle  
      • Abstain from sexual intercourse or  
      • Use additional contraceptive protection for the next 7 days 
    • Menstrual cycles have returned and >5 days since menstrual bleeding started 
      • Abstain from sexual intercourse or  
      • Use additional contraceptive protection for the next 7 days 

Postpartum (Not Breastfeeding)

  • Timing 
    • Start when the woman is medically eligible (MEC guidance) and meets ‘reasonably certain’ not pregnant criteria  
  • US MEC postpartum guidance (combined hormonal contraceptives)  
    • Avoid combined hormonal contraceptives during the first 3 weeks (risk of VTE)  
    • Caution: Women who are postpartum with additional risk factors for VTE should not use combined hormonal contraceptives 4–6 weeks after delivery (Please see ‘Primary Sources’ and ‘Related ObG Topics’ for further guidance on medical eligibility)
  • Back-up contraception 
    • <21 days postpartum 
      • No additional contraceptive protection needed
    • ≥21 days postpartum and whose menstrual cycles have not returned  
      • Abstain from sexual intercourse or  
      • Use additional contraceptive protection for the next 7 days 
    • Menstrual cycles have returned and it has been >5 days since menstrual bleeding started 
      • Abstain from sexual intercourse or  
      • Use additional contraceptive protection for the next 7 days 

Postabortion (Spontaneous or Induced) 

  • Timing: 
    • Start combined hormonal contraception within the first 7 days following first-trimester or second-trimester abortion, including immediately postabortion  
  • Back-up contraception
    • If combined hormonal contraception not started at time of surgical abortion  
      • Abstain from sexual intercourse or  
      • Use additional contraceptive protection for the next 7 days

SYNOPSIS:

There may be times there is uncertainty whether a woman is pregnant. According to the CDC, “the benefits of starting combined hormonal contraceptives likely exceed any risk; therefore, starting combined hormonal contraceptives should be considered at any time, with a follow-up pregnancy test in 2–4 weeks.” In a situation where a woman needs to use additional contraceptive protection when making the switch to combined hormonal contraception, consider continuing previous contraceptive methods for 7 days after starting combined hormonal contraception

KEY POINTS

Need for Routine Follow-Up

  • The CDC states that if a patient is otherwise healthy, “No routine follow-up visit is required”
  • Women should be advised to return at any time to discuss
    • Side effects | Desire to change contraceptive method | Any other issues or concerns
  • At other routine visits, assess
    • Patient satisfaction | Concerns
    • Change in health status and medications that may impact use of combined hormonal contraceptives (e.g., move to MEC category 3 and 4 conditions)
    • Blood pressure
    • Weight changes, including if patients are concerned regarding perceived changes

Switching from Another Contraceptive Method 

  • Timing 
    • Start at any time if ‘reasonably certain’ not pregnant criteria are met  
    • Waiting for her next menstrual cycle is unnecessary
  • Back-up contraception  
    • If combined hormonal contraception started >5 days since menstrual bleeding started 
      • Abstain from sexual intercourse or  
      • Use additional contraceptive protection for the next 7 days 

Switching from an IUD

  • If the woman has had sexual intercourse since the start of her current menstrual cycle and it is >5 days since menstrual bleeding started, consider any of the following  
    • Retain the IUD for at least 7 days after combined hormonal contraception initiated and return for IUD removal or  
    • Abstain from sexual intercourse or use barrier contraception for 7 days before removing the IUD and switching 
  • If cannot return for IUD removal and has not abstained from sexual intercourse or used barrier contraception for 7 days 
    • Use emergency contraceptive pills at the time of IUD removal 
    • Combined hormonal contraceptives can be started immediately after use of emergency contraceptive pills (except for ulipristal acetate) 
    • Ulipristal acetate: Combined hormonal contraceptives can be started no sooner than 5 days after use  
  • Note: The CDC considers IUDs separately because in theory, if a woman has had sexual intercourse and it is >5 days from the time of her period, residual sperm could still potentially be active with a risk for fertilization

VTE WARNING Category 3 or 4 (risk outweigh benefits or unacceptable risk)

The following factors elevate risk of VTE sufficiently to classify as 3 or 4 and alternate methods should be used

  • Smoking ≥35 years of age
  • Postpartum <21 days
  • Postpartum 21-42 days with additional risk factors
    • ≥35 years of age | Previous VTE | Thrombophilia | Immobility | Transfusion at delivery | Peripartum Cardiomyopathy | BMI ≥30 | PPH | Postcesarean delivery | preeclampsia | smoking
  • Major surgery with immobilization
  • History of DVT or PE
  • Hereditary thrombophilia including antiphospholipid syndrome
  • Inflammatory Bowel Disease with
    • Active or extensive disease | Surgery | Immobilization | Steroid use | Vitamin deficiencies | Fluid depletion
  • SLE with positive or unknown antiphospholipid antibodies
  • Superficial DVT (acute or history)

Learn More – Primary Sources:

CDC: U.S. Selected Practice Recommendations for Contraceptive Use, 2016

CDC MEC: Classifications for Combined Hormonal Contraceptives

ACOG Practice Bulletin 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions

CDC: Effectiveness of Family Planning Methods

WHO: Family planning/contraception methods

Take a post-test and get CME credits

TAKE THE POST TEST

Want to hear about the latest clinical summaries?

Get Your ObG Newsletter »

image_pdfFavoriteLoadingFavorite

< Previous
All GYN Posts
Next >

Related ObG Topics:

Practical info for your gynecology practice
Hormonal Contraception Benefits – Beyond Pregnancy Prevention
Emergency Contraception: What, When and How?
ACOG & SMFM Guidance on the Use of IUDs and Contraceptive Implants
IUDs and Implants: How to Manage Potential LARC Complications
CDC Resources: Contraception in Women with Medical Conditions (US MEC)
No Restrictions: ACOG Supports Over-the-Counter Access to Hormonal Contraception

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site